



# CNA Diagnostics Inc.

- Proprietary technology that identifies chronic diseases at early stages.
- Building a portfolio of commercial tests to diagnose highest impact diseases: bovine, porcine, equine, canine, feline, and human.
- Pending distribution through license agreements with well-known major industry participants for 67 countries.
- High barriers to entry, seasoned leadership, proven science.
- \$1M investment all inclusive for each new test developed with each test having significant commercial potential.

CNA Diagnostics Inc. (CNAD) is a Molecular Diagnostics company that is close to commercialization - developing tests for a wide spectrum of human and animal diseases long before the presence of the first clinical signs.

Our technology has the ability to detect multiple human and animal diseases before the occurrence of the first clinical signs, which indicate that a disease or infection exists.



## Circulating Nucleic Acids (CNA)

Body responds to challenges as it fights to return to normal.

Cells die as part of normal life (Apoptosis). DNA information regarding cell activity is released into the blood and protected in a double membraned vesicle.

Informative molecules packaged in vesicles enter into cells in another tissue and cause a reaction by the cells of this tissue.



## Go to Market Plan

- CNAD is a molecular diagnostics company with an expanding IP biomarker portfolio, which will be monetized through the sale of testing distribution rights.
- Alpha field tests for Johnes and Bovine Respiratory Disease planned beginning Q4 2017, followed by full product roll out.
- Department of National Defense Contract for Human Sepsis (full cost recovery only).
- Partnerships with distributors established.

Strategic partnerships  
(pending) with distributors  
in specific verticals and regions.

European distributor for 67 countries (Europe, Russia,  
North Africa, Middle East) re. bovine and porcine diseases.

Feedlot Health Management Services - Canada.

Developing partnership with companion animal hospital  
operator in USA for canine and feline diseases.

## Significant Access to Samples with Multiple Partners

(agreements in place)



## Management

David L. Gordon, Bcomm, PMP, CFA CEO, CFO

David is a business and financial professional with +15 years' experience optimizing business performance and effectively deploying capital to maximize an organization's potential. David has developed and lead high functioning teams, solved complex financial and cultural based organizational problems and is experienced in the unique challenges facing small and quickly growing entities.

David has previously held positions as an Investment Analyst with AIC Ltd, as a Management Consultant with Western Management Consultants, as an Investment Banking Associate with CIBC, and as the Leader of Strategy and Performance for a large public organization. David has worked on investor campaigns for many technology driven organizations. He holds a Chartered Financial Analyst (CFA) designation and is a Project Management Professional (PMP). David is a published author on strategy execution.

Dr. Christoph W. Sensen CSO

A founding member of CNA Diagnostics Inc., Dr. Sensen is a University Professor for Computational Biotechnology at the Graz University of Technology in Austria and an Adjunct Professor at the University of Calgary's Faculty of Medicine, Department of Biochemistry and Molecular Biology. He participated in several large-scale Genome Research programs, including two for the development of markers for CWD and BSE, and co-Author on more than 100 peer-reviewed articles and has edited or published six books in the field of Genome Research and Bioinformatics. Dr. Sensen is a reviewer for granting agencies and Journals; and Chief Editor at Journal of Biotechnology (Elsevier).

Previously he worked for seven years as a Research Officer at the National Research Council of Canada's Institute for Marine Biosciences (NRC-IMB) and as a visiting scientist at the European Molecular Biology Laboratory (EMBL) in Heidelberg (13 months). He studied Biology in Mainz, Düsseldorf and Cologne and obtained a Dr. rer. nat. degree from the University of Cologne in 1994.

## Share Structure

15.0M Common Shares • 0.5M Options • 2.4M Warrants

## Board of Directors

Dr. Greg Andrews  
Chairman, Director

Alec Milne Director

Dr. G. Kee Jim Director

Dennis L. Nerland, QC Director

Dr. Christoph W. Sensen Director

## Advisory Board

Dr. Robert B. Church

Dr. David Chalack



CNA Diagnostics Inc.